These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9743016)

  • 1. Combined interferon-alpha and interleukin-2 as adjuvant treatment for melanoma.
    Dummer R; Hauschild A; Henseler T; Burg G
    Lancet; 1998 Sep; 352(9131):908-9. PubMed ID: 9743016
    [No Abstract]   [Full Text] [Related]  

  • 2. [Development of interferon antibodies during the treatment of skin diseases with low-dose recombinant interferon alpha-2a].
    Corbillet V; Celerier P; Lebon P; Litoux P; Dreno B
    Ann Med Interne (Paris); 1995; 146(6):399-403. PubMed ID: 8597337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Protocol for optimal therapy of malignant melanoma in the metastatic stage by the Dermatologic Oncology Working Group].
    Hauschild A
    Hautarzt; 1996 Jan; 47(1):67-8. PubMed ID: 8835010
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful treatment of cutaneous metastatic melanoma with high-dose intralesional interleukin-2 treatment combined with cryosurgery.
    Martinez-Lopez A; Almazan-Fernandez FM; Perez-Lopez I; Aguayo-Carreras P; Salvador-Rodriguez L; Cuenca-Barrales C; Arias-Santiago S
    Dermatol Ther; 2018 Jul; 31(4):e12612. PubMed ID: 29766618
    [No Abstract]   [Full Text] [Related]  

  • 5. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [High-dose interferon-alpha and adjuvant treatment of melanoma with poor prognosis: requiem for a drug marketing license?].
    Saiag P
    Ann Dermatol Venereol; 1999 Mar; 126(3):211-3. PubMed ID: 10394432
    [No Abstract]   [Full Text] [Related]  

  • 7. [Imiquimod, pegylated interferon-alpha-2b and interleukin-2 in the treatment of cutaneous melanoma metastases].
    Loquai C; Nashan D; Metze D; Beiteke U; Rüping KW; Luger TA; Grabbe S
    Hautarzt; 2004 Feb; 55(2):176-81. PubMed ID: 14968329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of melanoma].
    Dréno B; Wallon-Dumont G
    Presse Med; 2003 Jan; 32(1):39-43. PubMed ID: 12610396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Where are we with adjuvant therapy of stage III and IV melanoma in 2009?
    Fecher LA; Flaherty KT
    J Natl Compr Canc Netw; 2009 Mar; 7(3):295-304. PubMed ID: 19401062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Decreased rate of progression and induction of tumor-specific immune response by adjuvant immunotherapy in stage IV melanoma].
    Enk AH; Wölfel T; Knop J
    Hautarzt; 1999 Feb; 50(2):103-8. PubMed ID: 10097952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More on cutaneous reactions to recombinant cytokine therapy.
    Le Gal FA; Paul C; Chemaly P; Dubertret L
    J Am Acad Dermatol; 1996 Oct; 35(4):650-1. PubMed ID: 8859310
    [No Abstract]   [Full Text] [Related]  

  • 12. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.
    Legha SS
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S39-43. PubMed ID: 9122733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant interferon in the treatment of melanoma.
    Middleton MR
    Br J Cancer; 1999 Aug; 80(11):1679-80. PubMed ID: 10468281
    [No Abstract]   [Full Text] [Related]  

  • 15. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
    Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
    Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biotherapy skin reaction.
    Newton S; Jackowski C; Marrs J
    Clin J Oncol Nurs; 2002; 6(3):181-2. PubMed ID: 11998617
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvant interferon alfa-2b for high-risk melanoma.
    Retsas S
    J Clin Oncol; 1996 Jun; 14(6):1968-9. PubMed ID: 8656272
    [No Abstract]   [Full Text] [Related]  

  • 18. [Comment on the contribution by C. Garbe et al.: Combination of interferon-alpha with cytostatic drugs: promising therapeutic approach in metastatic melanoma].
    Kleeberg UR; Kölmel KF
    Hautarzt; 1992 Nov; 43(11):737-8. PubMed ID: 1468937
    [No Abstract]   [Full Text] [Related]  

  • 19. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group.
    Pehamberger H; Soyer HP; Steiner A; Kofler R; Binder M; Mischer P; Pachinger W; Auböck J; Fritsch P; Kerl H; Wolff K
    J Clin Oncol; 1998 Apr; 16(4):1425-9. PubMed ID: 9552047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment.
    Bramlette TB; Lawson DH; Washington CV; Veledar E; Johns BR; Brisman SF; Abramova L; Chen SC
    Dermatol Surg; 2007 Jan; 33(1):11-6. PubMed ID: 17214673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.